Wall Street analysts expect that BeiGene (NASDAQ:BGNE) will report ($1.94) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for BeiGene’s earnings, with the lowest EPS estimate coming in at ($2.00) and the highest estimate coming in at ($1.87). BeiGene posted earnings per share of ($1.27) in the same quarter last year, which indicates a negative year over year growth rate of 52.8%. The company is expected to issue its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that BeiGene will report full-year earnings of ($7.69) per share for the current year, with EPS estimates ranging from ($8.60) to ($6.77). For the next fiscal year, analysts anticipate that the company will post earnings of ($7.90) per share, with EPS estimates ranging from ($8.47) to ($7.33). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover BeiGene.
BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The business had revenue of $18.17 million during the quarter, compared to the consensus estimate of $23.00 million.
BGNE stock traded up $1.75 during trading on Monday, reaching $166.23. 249,510 shares of the company’s stock were exchanged, compared to its average volume of 405,226. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.02 and a current ratio of 6.09. BeiGene has a 1-year low of $34.36 and a 1-year high of $182.79. The firm has a market capitalization of $8,810.37, a PE ratio of -74.54 and a beta of 0.22.
In other news, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were bought at an average price of $101.00 per share, with a total value of $199,999,998.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Liang sold 10,872 shares of the business’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04. Following the sale, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,493,015.04. The disclosure for this sale can be found here. Insiders sold a total of 194,210 shares of company stock worth $29,041,676 in the last three months. Company insiders own 19.90% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Bank of Montreal Can raised its position in shares of BeiGene by 3.8% during the fourth quarter. Bank of Montreal Can now owns 16,186 shares of the company’s stock worth $1,581,000 after purchasing an additional 600 shares during the period. Vident Investment Advisory LLC raised its position in shares of BeiGene by 2.6% during the third quarter. Vident Investment Advisory LLC now owns 29,191 shares of the company’s stock worth $3,020,000 after purchasing an additional 733 shares during the period. TD Asset Management Inc. raised its position in shares of BeiGene by 3.5% during the third quarter. TD Asset Management Inc. now owns 23,568 shares of the company’s stock worth $2,437,000 after purchasing an additional 800 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of BeiGene during the fourth quarter worth $182,000. Finally, Comerica Bank acquired a new stake in shares of BeiGene during the fourth quarter worth $246,000. 51.47% of the stock is currently owned by institutional investors.
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.